InsiderTrades.com logo
The Best AI Stock to Own in the World Today is Trading for Just $25
From Banyan Hill Publishing   |   Ad
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
See how you can invest alongside him
Regina M. Paglia net worth and biography
  • Phone
  • Email
  • Website

Regina Paglia Biography and Net Worth

Insider of Dicerna Pharmaceuticals

Presently, Regina M. DeTore Paglia is Senior Vice President-Human Resources of Dicerna Pharmaceuticals, Inc.

She previously occupied the position of Vice President-Human Resources of Mascoma Corp., Senior Vice President-Human Resources at PTTGC Innovation America Corp., Manager-Human Resources at FMR LLC, Senior Vice President-Human Resources of Paratek Pharmaceuticals, Inc., Vice President-Human Resources for Sunovion Pharmaceuticals, Inc. and Director-Human Resources for Tufts Associated Health Plans, Inc.

She received a graduate degree from Framingham State College and an undergraduate degree from Sawyer Business School.

What is Regina M. Paglia's net worth?

The estimated net worth of Regina M. Paglia is at least $48,501.18 as of June 25th, 2021. Ms. Paglia owns 1,269 shares of Dicerna Pharmaceuticals stock worth more than $48,501 as of April 26th. This net worth approximation does not reflect any other investments that Ms. Paglia may own. Learn More about Regina M. Paglia's net worth.

How do I contact Regina M. Paglia?

The corporate mailing address for Ms. Paglia and other Dicerna Pharmaceuticals executives is 33 HAYDEN AVENUE, LEXINGTON MA, 02421. Dicerna Pharmaceuticals can also be reached via phone at (617) 621-8097 and via email at [email protected]. Learn More on Regina M. Paglia's contact information.

Has Regina M. Paglia been buying or selling shares of Dicerna Pharmaceuticals?

Regina M. Paglia has not been actively trading shares of Dicerna Pharmaceuticals in the last ninety days. Most recently, Regina M. Paglia sold 1,000 shares of the business's stock in a transaction on Friday, June 25th. The shares were sold at an average price of $38.00, for a transaction totalling $38,000.00. Following the completion of the sale, the insider now directly owns 1,269 shares of the company's stock, valued at $48,222. Learn More on Regina M. Paglia's trading history.

Who are Dicerna Pharmaceuticals' active insiders?

Dicerna Pharmaceuticals' insider roster includes Shreeram Aradhye (EVP), Bob Brown (EVP), Robert Ciappenelli (Insider), Douglas Fambrough (CEO), Marc Kozin (Director), Regina Paglia (Insider), James Weissman (COO), and Ling Zeng (Insider). Learn More on Dicerna Pharmaceuticals' active insiders.

Regina M. Paglia Insider Trading History at Dicerna Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/25/2021Sell1,000$38.00$38,000.001,269View SEC Filing Icon  
6/22/2021Sell18,435$36.99$681,910.6514,019View SEC Filing Icon  
6/16/2021Sell31,564$35.63$1,124,625.32381View SEC Filing Icon  
6/1/2021Sell4,431$30.94$137,095.144,431View SEC Filing Icon  
5/3/2021Sell4,431$30.28$134,170.684,431View SEC Filing Icon  
4/1/2021Sell4,431$25.86$114,585.664,431View SEC Filing Icon  
1/25/2021Sell6,326$25.00$158,150.006,326View SEC Filing Icon  
11/4/2020Sell30,000$22.75$682,500.0030,000View SEC Filing Icon  
See Full Table

Regina M. Paglia Buying and Selling Activity at Dicerna Pharmaceuticals

This chart shows Regina M Paglia's buying and selling at Dicerna Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Dicerna Pharmaceuticals Company Overview

Dicerna Pharmaceuticals logo
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.
Read More

Today's Range

Now: $38.22
Low: $38.22
High: $38.22

50 Day Range

MA: $38.12
Low: $37.81
High: $38.25

2 Week Range

Now: $38.22
Low: $19.06
High: $40.14

Volume

N/A

Average Volume

1,344,033 shs

Market Capitalization

$2.99 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8
The Best AI Stock to Own in the World Today is Trading for Just $25
From Banyan Hill Publishing   |   Ad
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
See how you can invest alongside him